Fate Therapeutics Reports New Employee Inducement Awards

Got story updates? Submit your updates here. ›

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that on February 1, 2026, it granted a newly-hired non-executive employee non-qualified stock options to purchase 120,000 shares of the company's common stock and restricted stock units (RSUs) representing 90,000 shares. The grants were approved by the Compensation Committee and granted under the company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the company.

Why it matters

The announcement of new employee inducement awards provides insight into Fate Therapeutics' efforts to expand its workforce and build out its pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. These types of equity grants are common in the biotech industry as a way to attract and retain top talent.

The details

The stock options will vest over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% vesting in approximately equal monthly installments over the following thirty-six months. The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date. Both the stock options and RSUs are subject to the employee being continuously employed by the company through each vesting date.

• The grants were made on February 1, 2026.
• The stock options have a per share exercise price of $1.19, which was the closing price per share of the company's common stock as reported by NASDAQ on January 30, 2026.